Esoterix Clinical Trials Services, a division of LabCorp, entered a strategic alliance with the David H. Murdock Research Institute (DHMRI) to provide its clients with access to assay development services. Assays developed at DHMRI will be transferred to LabCorp Clinical Trials labs worldwide to support global clinical studies. The agreement also provides a mechanism for downstream commercialization of companion diagnostics and other biomarker assays once clinical validation has been established.

“With the addition of DHMRI’s discovery capabilities, LabCorp offers its clinical trials clients the most complete suite of biomarker development tools in the industry,” said Dr. David Johnston, senior vice president and Global Head of Clinical Trials at LabCorp. “Our collaboration with DHMRI exemplifies our strong commitment to providing cutting-edge services to our clients.”

The services available to clients through DHMRI include biomarker discovery and proof of concept assay development to support early and late stage drug discovery and development. DHMRI has capabilities ranging from profiling at the genetic, biochemical, cellular and in vivo levels to clinical immune system monitoring using multiparameter flow cytometry and multiplexed protein analysis and quantitative gene expression.